^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ALTA-002

    i
    Other names: ALTA-002, TAC-002, SIRPα TRAAC, anti-SIRPα antibody-Toll-like Receptor Agonist Antibody Conjugate, ALTA002, ALTA 002, TAC002, TAC 002
    Associations

    News

    Trials
    Company:
    ALX Oncology, Tallac Therap
    Drug class:
    TLR9 agonist, SIRPA antagonist
    Related drugs:
    Associations

    News

    Trials
    3years
    ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (SITC 2021)
    Conclusions These results demonstrate the unique properties of systemically administered ALTA-002, which integrates TLR9 activation and blockade of CD47-SIRPα interaction on myeloid cells to engender both innate and adaptive anti-tumor immune responses. These data support the development of ALTA-002 as an anti-cancer therapeutic for a variety of tumor malignancies.
    IO biomarker
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ALTA-002